Use of Biologics in Pediatric Patients and Conversations with Parents
Robert Sporter, MD, discusses the initial conversations he has with pediatric patients and their parents when considering biologic therapies, addressing the risks associated with not treating the condition, such as compromised lung function and increased steroid use. He emphasizes the importance of communicating a comprehensive treatment plan, including contingencies for cases where a particular therapy may not be effective.
EP: 1.External Factors and Seasonality of Asthma
EP: 2.Endotypes and Phenotypes in Asthma
EP: 3.Type 2 Inflammation and Biomarkers in Asthma
EP: 4.Moderate/Severe/Uncontrolled Asthma Classification
EP: 5.Thinking About Endotypes when Managing Asthma
EP: 6.Use of Oral Corticosteroids in Asthma
EP: 7.High Oral Corticosteroid Dose and Exposure in Asthma
EP: 8.Oral Corticosteroid Overuse and Uncontrolled Asthma
EP: 9.Biomarkers and Eosinophil Levels in Severe or Uncontrolled Asthma
EP: 10.Biologics in Asthma
EP: 11.GINA Guidelines and Biologics for Treatment of Asthma
EP: 12.Use of Biologics for Asthma in Patients with Allergies
EP: 13.Treatment of Asthma in Pediatric Patients
EP: 14.Atopic March in Pediatric Patients
Now Viewing
EP: 15.Use of Biologics in Pediatric Patients and Conversations with Parents
EP: 16.Biologic Options in Pediatric Asthma
Related Videos
Related Content
